Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion, Biogen, AB Science, Ionis, Biohaven, MediciNova, NeuroSense
July 19, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 19, 2023 (GLOBE NEWSWIRE) -- Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion,...
Amyotrophic Lateral Sclerosis Treatment Market to Reach US$ 594.1 Million in 2031, Expanding at a CAGR of 5.5%: TMR Report
June 26, 2023 13:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. – In 2022, the global industry was estimated to be worth $594.1 million. It is expected to...
PathMaker Neurosystems Receives $200,000 START Award from MassVentures
June 05, 2023 06:00 ET
|
PathMaker Neurosystems Inc.
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...
AB Science résume les messages clés de sa participation à une table ronde lors du ALS Drug Development Summit 2023
May 17, 2023 14:15 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE RÉSUME LES MESSAGES CLÉS DE SA PARTICIPATION À UNE TABLE RONDE LORS DU ALS DRUG DEVELOPMENT SUMMIT 2023 (BOSTON, ETATS-UNIS) Paris, 17 mai 2023, 20h00 AB Science SA...
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
May 17, 2023 14:15 ET
|
AB Science
PRESS RELEASE AB SCIENCE SUMMARIZES KEY MESSAGES FROM ITS PARTICIPATION TO A PANEL DISCUSSION AT THE 2023 ALS DRUG DEVELOPMENT SUMMIT (BOSTON, USA) Paris, 17 May, 2023, 8:00pm CET AB Science SA...
AB Science annonce que Health Canada a repris la revue du dossier d’enregistrement du masitinib dans la sclérose latérale amyotrophique, suite à l’examen préliminaire de la réponse soumise par AB Science
May 09, 2023 12:06 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE HEALTH CANADA A REPRIS LA REVUE DU DOSSIER D’ENREGISTREMENT DU MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE, SUITE A L’EXAMEN PRELIMINAIRE DE LA...
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
May 09, 2023 12:06 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS RESUMED ITS REVIEW OF THE NEW DRUG SUBMISSION FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS, FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE...
Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
April 25, 2023 15:52 ET
|
Muscular Dystrophy Association
New York, April 25, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of Qalsody (tofersen), for the...
Muscular Dystrophy Association Announces Programming for ALS Awareness Month
April 24, 2023 09:00 ET
|
Muscular Dystrophy Association
New York, April 24, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced programming and fundraising events in support of people living with Amyotrophic Lateral...
AB Science annonce l’obtention d’un brevet sur le masitinib au Japon pour le traitement de la sclérose latérale amyotrophique, renforçant ainsi la position de la société en matière de propriété intellectuelle jusqu’en 2037
April 18, 2023 12:55 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE L'OBTENTION D'UN BREVET SUR LE MASITINIB AU JAPON POUR LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE, RENFORÇANT AINSI LA POSITION DE LA SOCIÉTÉ EN...